文献速递肥胖与代谢综合征

生长分化因子15受体激动剂在健康或肥胖人群中的随机安慰剂对照试验

A Growth Differentiation Factor 15 Receptor Agonist in Randomized Placebo-Controlled Trials in Healthy or Obese Persons.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

MBL949是一种半衰期延长的重组人GDF15二聚体。在两项随机安慰剂对照临床试验中,超重/肥胖健康志愿者(n=65)接受单次递增剂量(0.03至20 mg)皮下注射,肥胖参与者(n=126)每两周皮下注射共8次。结果:单次给药后半衰期18至22天,较高剂量有体重下降证据;2期试验中14周每两周给药后体重下降极小;胃肠道不良事件最常见,安全性可接受。

要点

  • MBL949在非临床种属中减少摄食和体重,但2期试验中14周每两周给药后体重下降极小。
  • 单次递增剂量试验中MBL949平均终末半衰期为18至22天,较高剂量有体重下降证据。
  • MBL949在测试剂量范围内安全且总体耐受,胃肠道不良事件最常见。

核心结论

  • MBL949的半衰期延长支持每两周给药。
  • MBL949具有可接受的安全性特征。
  • 在非临床种属中观察到的显著体重下降未转化为人体体重下降疗效。

研究设计与样本

  • MBL949先在多个非临床种属中评估,随后在2项随机安慰剂对照临床试验中评估。
  • 1期首次人体单次递增剂量试验:超重和肥胖健康志愿者(n=65)皮下注射MBL949或安慰剂,剂量范围0.03至20 mg。
  • 2期试验:肥胖参与者(n=126)每两周皮下注射MBL949或安慰剂共8次,采用5种基于1期数据预测有效的不同剂量方案。

主要发现

  • 在非临床种属(小鼠、大鼠、犬和猴)中,MBL949总体安全有效,减少摄食和体重。
  • 非临床种属中体重下降主要来自脂肪减少,代谢终点改善。
  • 1期单次递增剂量试验中,超重或肥胖健康成人平均终末半衰期为18至22天,较高剂量有体重下降证据。
  • 2期试验中,每两周给予MBL949共14周后体重下降极小。
  • MBL949在人体测试剂量范围内安全且总体耐受,胃肠道系统不良事件最常见。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Growth differentiation factor 15 (GDF15), a divergent member of the TGF-β superfamily, signals via the hindbrain glial-derived neurotrophic factor receptor alpha-like and rearranged during transfection receptor co-receptor (GFRAL-RET) complex. In nonclinical species, GDF15 is a potent anorexigen leading to substantial weight loss. MBL949 is a half-life extended recombinant human GDF15 dimer. METHODS: MBL949 was evaluated in multiple nonclinical species, and then in humans, in 2 randomized and placebo-controlled clinical trials. In the phase 1, first-in-human, single ascending dose trial, MBL949 or placebo was injected subcutaneously to overweight and obese healthy volunteers (n = 65) at doses ranging from 0.03 to 20 mg. In phase 2, MBL949 or placebo was administered subcutaneously every other week for a total of 8 doses to obese participants (n = 126) in 5 different dose regimens predicted to be efficacious based on data from the phase 1 trial. RESULTS: In nonclinical species, MBL949 was generally safe and effective with reduced food intake and body weight in mice, rats, dogs, and monkeys. Weight loss was primarily from reduced fat, and metabolic endpoints improved. A single ascending dose study in overweight or obese healthy adults demonstrated mean terminal half-life of 18 to 22 days and evidence of weight loss at the higher doses. In the phase 2, weight loss was minimal following biweekly dosing of MBL949 for 14 weeks. MBL949 was safe and generally tolerated in humans over the dose range tested, adverse events of the gastrointestinal system were the most frequent observed. CONCLUSION: The prolonged half-life of MBL949 supports biweekly dosing in patients. MBL949 had an acceptable safety profile. The robust weight loss observed in nonclinical species did not translate to weight loss efficacy in humans.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Smith WB, Nguyen D, Clough T, et al. A Growth Differentiation Factor 15 Receptor Agonist in Randomized Placebo-Controlled Trials in Healthy or Obese Persons. J Clin Endocrinol Metab. 2025. PMID: 39148430. doi:10.1210/clinem/dgae550

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。